IMNM Immunome announces first patient dosed in phase 1 trial evaluating im-3050, an fap-targeted radioligand therapy, in patients with fap-e
IMNM Immunome announces first patient dosed in phase 1 trial evaluating im-3050, an fap-targeted radioligand therapy, in patients with fap-expressing advanced solid tumors Immunome - phase 1 trial to evaluate safety and preliminary activity of im-3050
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.